Dose-Dependent Efficacy of Aripiprazole in Treating Patients With Schizophrenia or Schizoaffective Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Dose-Dependent Efficacy of Aripiprazole in Treating Patients With Schizophrenia or Schizoaffective Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Purpose: To compare the efficacy and tolerability of different administration strategies of aripiprazole.Methods: We searched MEDLINE, EMBASE, the Cochrane Central, Web of Science, China National Knowledge Infrastructure(CNKI), and Wanfang Data Knowledge Service Platform(Wanfang) for randomized cont...

Full description

Bibliographic Details
Main Authors:	Li Qian, Liao Xuemei, Li Jitao, Su Yun'Ai, Si Tianmei
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-08-01
Series:	Frontiers in Psychiatry
Subjects:	schizophrenia schizoaffective disorder aripiprazole efficacy strategy systematic review
Online Access:	https://www.frontiersin.org/articles/10.3389/fpsyt.2021.717715/full

Similar Items

Therapy of Schizoaffective Disorder and Paranoid Schizophrenia with Episodic Course
by: L. A. Ivanova, et al.
Published: (2019-05-01)

Paranoid schizophrenia versus schizoaffective disorder: Neuropsychological aspects
by: Leposavić Ljubica, et al.
Published: (2015-01-01)

Religious Coping Strategies for Religious Patients with Schizophrenia and Schizoaffective Disorder
by: E. Gedevani, et al.
Published: (2022-06-01)

The use of technologies and social media in patients with schizophrenia and schizoaffective disorder
by: O. Elleuch, et al.
Published: (2022-06-01)

Aripiprazole for refractory catatonic schizophrenia – A case report
by: Saisudha N V Gorthi, et al.
Published: (2015-01-01)

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
by: Saki Hattori, et al.
Published: (2023-03-01)

Side Effects of Clozapine Treatment in Patients with Schizophrenia and Schizoaffective Disorder and Their Role in the Discontinuation of Treatment
by: Rümeysa Taşdelen, et al.
Published: (2023-03-01)

Neurophysiological distinction between schizophrenia and schizoaffective disorder
by: Daniel H Mathalon, et al.
Published: (2010-01-01)

Prodrome of Paranoid Schizophrenia with Episodic Type of Course and Schizoaffective Structure of Manifest Episode
by: Alexander S. Bobrov, et al.
Published: (2014-06-01)

Schizophrenia: effects of aripiprazole in metabolic syndrome
by: Deborah Galvão Coelho da Silva, et al.
Published: (2019-11-01)

Aripiprazole LAI two‐injection start in a 16 year‐old adolescent with schizophrenia
by: Virginio Salvi, et al.
Published: (2022-06-01)

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
by: Daniel Schöttle, et al.
Published: (2018-11-01)

Determination of Changes in Blood Biomarker Levels in Antipsychotic Polypharmacy and Aripiprazole Monotherapy in Patients With Long-term Schizophrenia
by: Venus Vatankhah, et al.
Published: (2019-12-01)

Differential Diagnosis of Schizophrenia and Schizoaffective Disorder: the Role of Emotional Content of Memories
by: Malahat Amani, et al.
Published: (2018-01-01)

Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level
by: Zhi P, et al.
Published: (2018-08-01)

Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen
by: S.L. Romero Guillena, et al.
Published: (2022-06-01)

Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder
by: Atiqul Haq Mazumder, et al.
Published: (2021-05-01)

Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study
by: José Manuel Olivares, et al.
Published: (2021-01-01)

Recurrent Episodes of Paraphilic Behavior Possibly Associated With Olanzapine and Aripiprazole Treatment in a Patient With Schizophrenia
by: Maria-Ioanna Stefanou, et al.
Published: (2020-04-01)

A Perspective on a Possible Relation Between the Psychopathology of the Schizophrenia/Schizoaffective Spectrum and Unconjugated Bilirubin: A Longitudinal Protocol Study
by: João Gama Marques, et al.
Published: (2018-04-01)

Social and Neurocognitive Deficits in Remitted Patients with Schizophrenia, Schizoaffective and Bipolar Disorder
by: Liana Dehelean, et al.
Published: (2021-03-01)

Hyperprolactinaemia and menstrual irregularity emerging in association with risperidone use and treated with aripiprazole in an adolescent diagnosed with schizophrenia: a case report
by: Şermin Bilgen Ulgar, et al.
Published: (2018-10-01)

Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
by: Eiji Kirino
Published: (2017-11-01)

Switching Between Second-Generation Antipsychotics in Patients with Schizophrenia and Schizoaffective Disorder: 10-Year Cohort Study in Brazil
by: Izabela Fulone, et al.
Published: (2021-05-01)

Dynamics of mental state and prolactin levels in patients with chronic schizophrenia during aripiprazole therapy
by: L. N. Gorobets, et al.
Published: (2023-07-01)

Nonadherence after hospital discharge in patients with schizophrenia or schizoaffective disorder: A six-month naturalistic follow-up study
by: Dulcinea Vega, et al.
Published: (2021-07-01)

Ethnic minority inequalities in access to treatments for schizophrenia and schizoaffective disorders: findings from a nationally representative cross-sectional study
by: Jayati Das-Munshi, et al.
Published: (2018-04-01)

SCHIZOAFFECTIVE DISORDER WITH MANIC TYPE : A CASE REPORT
by: A.A. Gede Ocha Rama Kharisma Putra
Published: (2014-02-01)

Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study – CORRIGENDUM
by: José Manuel Olivares, et al.
Published: (2021-01-01)

Clinical experience with the new double aripiprazole depot regime in a psychiatric hospitalization unit
by: Á. Moleón Ruiz, et al.
Published: (2022-06-01)

Severe arrhythmia induced by orally disintegrating aripiprazole tablets (Bosiqing®): a case report
by: Shao Q, et al.
Published: (2015-12-01)

Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder
by: E.R. Bychkov, et al.
Published: (2011-11-01)

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study
by: Pierre-Michel Llorca, et al.
Published: (2022-05-01)

Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review
by: Kunal Maini, et al.
Published: (2021-07-01)

Augmentation of aripiprazole by flupenthixol decanoate in poorly responsive schizophrenia: a randomized clinical study
by: Saeed Shoja Shafti
Published: (2017-07-01)

Aripiprazole-induced skin rash
by: Santanu Nath, et al.
Published: (2016-01-01)

Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
by: Salzman PM, et al.
Published: (2017-04-01)

Recovery in schizophrenia: related factors in a group of patients followed up for 5 years in a private practice
by: Mustafa Yildiz
Published: (2017-10-01)

Effects of Aripiprazole on Olanzapine Population Pharmacokinetics and Initial Dosage Optimization in Schizophrenia Patients
by: Zhang C, et al.
Published: (2024-03-01)

Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole
by: Topolov Mariyan K., et al.
Published: (2016-03-01)